Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade

被引：27
|
作者：
Mittal, Deepak [1 ]
Vijayan, Dipti [1 ]
Smyth, Mark J. [1 ]
机构：
[1] QIMR Berghofer Med Res Inst, Immunol Canc & Infect Lab, Herston, Qld, Australia
来源：
CANCER DISCOVERY | 2018年 / 8卷 / 09期
关键词：
THERAPY; CELLS;
D O I：
10.1158/2159-8290.CD-18-0798
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Overexpression of CD38 after PD-1/PD-L1 blockade increases extracellular adenosine levels and may contribute to acquired resistance to anti-PD-1/PD-L1 therapy. (C) 2018 AACR.
引用
收藏
页码：1066 / 1068
页数：3
相关论文
共 50 条
  • [21] PD-L1 Expression in Mucosal Malignant Melanoma: Implications for PD-1/PD-L1 Blockade Therapy
    Lilo, Mohammed
    Berry, Sneha
    Xu, Haiying
    Ogurtsova, Aleksandra
    Lipson, Evan
    Taube, Janis
    MODERN PATHOLOGY, 2015, 28 : 123A - 123A
  • [22] PD-L1 Expression in Mucosal Malignant Melanoma: Implications for PD-1/PD-L1 Blockade Therapy
    Lilo, Mohammed
    Berry, Sneha
    Xu, Haiying
    Ogurtsova, Aleksandra
    Lipson, Evan
    Taube, Janis
    LABORATORY INVESTIGATION, 2015, 95 : 123A - 123A
  • [23] PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
    Bocanegra, Ana
    Blanco, Ester
    Fernandez-Hinojal, Gonzalo
    Arasanz, Hugo
    Chocarro, Luisa
    Zuazo, Miren
    Morente, Pilar
    Vera, Ruth
    Escors, David
    Kochan, Grazyna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (16) : 1 - 17
  • [24] PD-L1 copy number gains: a predictive biomarker for PD-1/PD-L1 blockade therapy?
    Inoue, Yusuke
    Osman, Murat
    Suda, Takafumi
    Sugimura, Haruhiko
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S199 - S202
  • [25] Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
    Verkleij, Christie P. M.
    Jhatakia, Amy
    Broekmans, Marloes E. C.
    Frerichs, Kristine A.
    Zweegman, Sonja
    Mutis, Tuna
    Bezman, Natalie A.
    van de Donk, Niels W. C. J.
    CANCERS, 2020, 12 (12) : 1 - 20
  • [26] PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
    B Paiva
    A Azpilikueta
    N Puig
    E M Ocio
    R Sharma
    B O Oyajobi
    S Labiano
    L San-Segundo
    A Rodriguez
    I Aires-Mejia
    I Rodriguez
    F Escalante
    A G de Coca
    A Barez
    J F San Miguel
    I Melero
    Leukemia, 2015, 29 : 2110 - 2113
  • [27] PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
    Paiva, B.
    Azpilikueta, A.
    Puig, N.
    Ocio, E. M.
    Sharma, R.
    Oyajobi, B. O.
    Labiano, S.
    San-Segundo, L.
    Rodriguez, A.
    Aires-Mejia, I.
    Rodriguez, I.
    Escalante, F.
    de Coca, A. G.
    Barez, A.
    San Miguel, J. F.
    Melero, I.
    LEUKEMIA, 2015, 29 (10) : 2110 - 2113
  • [28] New strategies with PD-1/PD-L1 blockade in lung cancer
    不详
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2023, 16 (SUPPL 3) : 54 - 58
  • [29] Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade
    Lee, Bo Ryeong
    Chae, Sehyun
    Moon, Jihyun
    Kim, Myeong Joon
    Lee, Hankyu
    Ko, Hyuk Wan
    Cho, Byoung Chul
    Shim, Hyo Sup
    Hwang, Daehee
    Kim, Hye Ryun
    Ha, Sang-Jun
    JCI INSIGHT, 2020, 5 (14)
  • [30] PD-L1/PD-1 blockade in breast cancer: The immunotherapy era
    Li, Chia-Jung
    Lin, Li-Te
    Hou, Ming-Feng
    Chu, Pei-Yi
    ONCOLOGY REPORTS, 2021, 45 (01) : 5 - 12
12345